Management Team

Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company’s diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical’s strategy and valuation from $25 million to $1.4 billion sale to GlaxoSmithKline.  As CEO of ProPhase Labs, he restructured the go-to-market strategy for the flagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for $50 million to Mylan.

ProPhase Labs is a fast-growing biotech, genomics and diagnostics company due to its commitment to growth, innovation, and execution excellence outlined in Ted’s high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics.  Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential.

He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors.

Jed A. Latkin served as a director and Chief Executive Officer of Navidea from October 2018, until October 2021. Mr. Latkin has more than 28 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals. He most recently was employed by Nagel Avenue Capital, LLC since 2010, and in that capacity he provided contracted services as a CEO/CFO for numerous healthcare related firms. Mr. Latkin worked for over ten years in Investment Banking at Citigroup, Morgan Stanley and Fleet Boston Robertson Stephens. He also spent five years as a Co-Portfolio Manager for ING Investment Management. Mr. Latkin earned a B.A from Rutgers University and a M.B.A. from Columbia Business School.

Prior to ProPhase Labs, Mr. Morse served as Global Controller and Chief Accounting Officer at multiple high-growth pre-IPO companies in the FinTech, EdTech and Asset Management sectors. Mr. Morse spent four years at MasterCard Worldwide and 10 years at The McGraw-Hill Companies and Standard & Poor’s. Mr. Morse began his career with four years in public accounting including two years with Ernst & Young LLP.

Jason drove explosive revenue growth at ProPhase Diagnostics, leading multiple areas including sales, business development, logistics operations, and account management. He oversaw the development of two CLIA-certified labs, generating approximately $200 million in revenues since 2021 and manages account managers and customer service reps who offer 24/7 service to exceed customer expectations. Jason now heads up business development for the rapid build-out of ProPhase’s Nebula Genomics business.

With a background in sales and development at top real estate firms, Jason is a graduate of the University of Maryland.

Sergio Miralles is an experienced IT Leader with over 12 years of experience in enterprise level Cybersecurity, Infrastructure, and Architecture. Sergio is responsible for ensuring a complete end-to-end technology solution that links its lab customers’ patient data via an interface to efficiently process and report results. Previously, Sergio founded and led a successful IT consulting firm overseeing 18 IT consultants. For the last five years, his primary focus has been on the medical, lab, and diagnostics business. Sergio holds several certifications from Cisco, ISC2, and CompTIA.

Kamal is co-founder of Nebula Genomics. He received his undergraduate degree at Harvard University and did graduate studies in computer science as a Gates-Cambridge Fellow at the University of Cambridge. Prior to founding Nebula, Kamal led teams at Google. For his work, Kamal has received multiple honors including being named to the Forbes 30 under 30 list.

Dr. Matthew Halpert, Ph.D. earned his doctorate at the University of Alabama-Birmingham (UAB), and then spent 10 years at Baylor College of Medicine in Houston as a cancer immunologist.  His research in the space of ‘immunity’ and ‘novel cancer treatments’ lead to several peer-reviewed publications and book chapters, hundreds of citations, a variety of patents, positions on multiple charitable boards, and establishment as one of the leading experts regarding cutting-edge mechanistic science as it pertains to the treatment of cancer.  His work has been advanced in several FDA clinical trials. 

Along with being a co-founder at Nebula Genomics, Dr. George Church is also Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org. His 1984 Harvard Ph.D. included the first methods for direct genome sequencing, molecular multiplexing & barcoding. This led to the first genome sequence (pathogen, Helicobacter pylori) in 1994. His innovations have contributed to nearly all “next-generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has co-authored 590 papers, 155 patent publications and  one book (Regenesis).

Dr. Russ Altman, with degrees from Harvard and Stanford, is a certified expert in internal medicine and clinical informatics. His career has been distinguished with awards, including the Presidential Early Career Award and NSF's CAREER award. He holds fellowships with ACP, ACMI, AIMBE, and AAAS, and is a member of the National Academy of Medicine. His leadership extends to serving as past president of ISCB and ASCPT. Dr. Altman has also shaped national health policy and regulation through his roles advising the FDA and NIH, and co-chairing the IOM Drug Forum, demonstrating his influence in the advancement of medical sciences and technology.

Dr. Patrick Merel, a molecular biology PhD from the University of Bordeaux, has made significant contributions to molecular diagnostics and genomics over 20 years in both academic (Bordeaux Blood Bank, University Hospital of Bordeaux) and industry roles. In San Diego, he consulted for Beckman Coulter and co-founded Portable Genomics and Edico Genome, the latter acquired by Illumina in 2018. Currently, as director at Abu Dhabi's Technology Innovation Institute, he integrates genomics, multi-omics, AI, and biotech, building on his work with the Omics Center at G42 Healthcare and the Emirati Genome Program.